Insight

Apr 3, 2024, 13:35

Kefah Mokbel: Insights into the management of Leptomeningeal Disease and clinical outcomes

Kefah Mokbel, Chair of The Multidisciplinary Breast Cancer Program at London Breast Institute, shared on LinkedIn:

“Insights into the management of Leptomeningeal disease (LMD) and clinical outcomes:

I would like to add the following comments:

In ER-positive breast cancer, Abemaciclib should be considered the CDK4/6 inhibitor of choice due to its superior penetration through the blood-brain barrier (BBB).

Intrathecal therapy remains underutilized in both research and clinical management settings.

Lumbar puncture for direct genomics analysis is also underutilized and warrants further exploration.

The role of PD-1 and PD-L1 inhibitors in patients with PD-L1 positive disease deserves further discussion (response rates exceeds 30%).”

Proceed to the article.
Source: Kefah Mokbel/LinkedIn

Abemaciclib cancer CDK4/6 inhibitors ER+ breast cancer Kefah Mokbel Leptomeningeal Disease LMD London Breast Institute OncoDaily Oncology PD-1 inhibitors PD-L1 inhibitors

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Bispecific Antibody M701 Offers a Novel Treatment Option for Malignant Ascites

Special Coverage